Adequacy of the preventive treatment of osteoporotic fractures in postmenopausal women;Adecuación del tratamiento preventivo de fracturas osteoporóticas en mujeres posmenopáusicas

Semergen

Volumn 36, Issue 3, 2010, Pages 121-127

  Amaya, M C ^a   Gomez M M ^a   Martinez M J ^a   Lendinez J M ^a  

^a Centro de Salud de Puerto Real   (Spain)

Author keywords

Osteoporosis; Postmenopause; Primary care; Treatment

Indexed keywords

EID: 77950593767     PISSN: 11383593     EISSN: 15788865     Source Type: Journal    
DOI: 10.1016/j.semerg.2009.12.004     Document Type: Article

References (21)

1. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position stament of the North American Menopause Society. Menopause 13 (2006) 340-367
2. Nacional Guideline Clearinghouse. Diagnosis and treatment of osteoporosis: 2006; 35 p.
3. Cheung A.M., Feig D.S., Kapral M., Díaz-Granados N., Dodin S., and The Canadian Task Force on Preventive Health Care. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 170 (2004)
4. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcio y vitamina D para la osteoporosis inducida por corticosteroides (Revisión Cochrane). En: La Cochrane Library Plus. Número 2, 2002. Oxford: Update Software.
5. Carter N.D., Khan K.M., McKay H.A., Petit M.A., Waterman C., Heinonen A., et al. Community-based exercise program reduces risk factors for falls in 65- to 75-year-old women with osteoporosis: randomized controlled trial. CMAJ 168 (2003) 997-1004
6. Chang JT, Morton SC, Rubenstein LZ, Mojica WA, Maglione M, Suttorp MJ, et al. Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials BMJ. 2004;328:680-3.
7. Kanis J.A., Gluer C.C., Committee of Scientific Advisors, and International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11 (2000) 192-202
8. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., et al. Mulitple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 (2002) 3609-3617
9. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 (2001) 333-340
10. Watts N.B., Josse R.G., Hamdy R.C., Hughes R.A., Manhart M.D., Barton I., et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88 (2003) 542-549
11. Torgerson D.J., and Bell-Syer S.E.M. Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials. JAMA 285 (2001) 2891-2897
12. Reginster J.-Y., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11 (2000) 83-91
13. Coyle D., Hadj Tahar A., Murphy G., Perras C., Skidmore B., Boucher M., et al. Teriparatide and bisphosphonates for treatment of osteoporosis in women: a clinical and economic analysis (2006), Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa p. 55
14. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85 (2000) 4118-4124
15. Blake G.M., and Fogelman I. Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy. Clin Interv Aging 1 (2006) 367-375
16. Stevenson M., Lloyd J.M., Nigris E., Brewer N., Davis S., and Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technology Assessment 9 (2005)
17. NICE technology appraisal guidance 160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. 2008. Disponible en: http://guidance.org.uk/TA160.
18. NICE technology appraisal guidance 161.Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. 2008. Disponible en: http://guidance.org.uk/TA161.
19. Terol C, Quintana-Cerezal JV, Santos-Alvero MJ, Corell M, Marcos P, Crespo AP. Análisis de la prescripción de antirresortivos en el tratamiento de la osteoporosis en Atención Primaria. Rev Valenciana de Medicina de Familia. N 40-41 www.svmyc.org
20. Arana-Arria E., Gutiérrez-Ibarluzeab I., Gutiérrez M.L., Ortueta P., Jiménez A.I., Sánchez A.M., et al. Análisis comparativo frente a la evidencia del manejo de la osteoporosis en una comarca de atención primaria. Aten Primaria 40 (2008) 549-554
21. Zwart M., Fradera M., Solanas P., González C., and Adalid C. Abordaje de la osteoporosis en un centro de atención primaria. Aten Primaria 33 4 (2004) 183-187